DOCS Price Prediction Next Week
Analysis and Insights
To predict the stock price of Doximity (DOCS) for the next trading week, we analyze both news sentiment and technical indicators.
News Sentiment Analysis:
- Bearish Options Activity: Heavy put volume has been observed, with 2,440 puts traded, primarily in the Apr-25 60 puts and Mar-25 62.5 puts, resulting in a high Put/Call Ratio of 6.93. This indicates strong bearish sentiment among traders.
- Analyst Ratings: Leerink Partners analyst Michael Cherny reiterated a Buy rating on Doximity with a price target of $90.00, suggesting long-term growth potential.
- Put Selling Risks: Selling puts on DOCS may not provide significant upside potential, as the seller only benefits if the stock price declines substantially.
Technical Analysis:
- Price Trends: DOCS is currently trading at $62.72, below its 20, 50, and 200-day moving averages, indicating a bearish trend.
- RSI: The RSI (6-day) is at 25.53, which is in oversold territory, suggesting a potential rebound.
- MACD: The MACD line is above the signal line, but the histogram is negative, indicating a bearish crossover.
- Fibonacci Levels: The stock is approaching the first support level at $61.50, with resistance at $73.90.
Price Prediction:
Given the bearish options activity and technical indicators, DOCS is likely to test the support level at $61.50 in the next trading week.
Recommendation:
Sell DOCS with a target price of $61.50.
DOCS Similar Chart Price Prediction
The price of DOCS is predicted to go up 29.21%, based on the high correlation periods with JOB. The similarity of these two price pattern on the periods is 98.29%.
DOCS
JOB
Up: 29.21%Similarity: 98.29%
DOCS Revenue Forecast
DOCS EPS Forecast
DOCS FAQs
What is DOCS revenue forecast for next quarter？
What is DOCS eps forecast for next quarter？
DOCS Analyst's Forecast
Steven Valiquette
Mizuho
Hold
2025-02-10
Price Target
$55 → $65
Downside
-21.82%
Mizuho raised the firm's price target on Doximity to $65 from $55 and keeps a Neutral rating on the shares. The company reported its third consecutive "beat and raise" quarter as it continues to increase engagement with physicians on its app, the analyst tells investors in a research note. The firm believes Doximity's new pharma client portal, which allows clients to more easily track marketing spend virtually real-time, is another key factor in accelerating revenue growth.
Stan Berenshteyn
Wells Fargo
Hold
2025-01-13
Price Target
$41 → $43
Downside
-13.5%
Scott Schoenhaus
Keybanc
Buy
2025-01-08
Price Target
$70 → $65
Upside
+18.18%
